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Abstract The identiﬁcation of epitopes that elicit cyto-
toxic T-lymphocyte activity is a prerequisite for the
development of cancer-speciﬁc immunotherapies. How-
ever, especially the parallel characterization of several
epitopes is limited by the availability of T cells. Micro-
arrays have enabled an unprecedented miniaturization and
parallelization in biological assays. Here, we developed
peptide microarrays for the detection of CTL activity.
MHC class I-binding peptide epitopes were pipetted onto
polymer-coated glass slides. Target cells, loaded with the
cell-impermeant dye calcein, were incubated on these
arrays, followed by incubation with antigen-expanded
CTLs. Cytotoxic activity was detected by release of calcein
and detachment of target cells. With only 200,000 cells per
microarray, CTLs could be detected at a frequency of 0.5%
corresponding to 1,000 antigen-speciﬁc T cells. Target
cells and CTLs only settled on peptide spots enabling a
clear separation of individual epitopes. Even though no
physical boundaries were present between the individual
spots, peptide loading only occurred locally and cytolytic
activity was conﬁned to the spots carrying the speciﬁc
epitope. The peptide microarrays provide a robust platform
that implements the whole process from antigen presenta-
tion to the detection of CTL activity in a miniaturized
format. The method surpasses all established methods in
the minimum numbers of cells required. With antigen
uptake occurring on the microarray, further applications are
foreseen in the testing of antigen precursors that require
uptake and processing prior to presentation.
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Introduction
The initiation and enhancement of cancer-speciﬁc CTL
responses hold great promise in the development of
effective novel cancer therapies [1–3]. In combination with
agents intended to promote the induction of immunity such
as adjuvants or dendritic cells, antigens are administered
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administration of HLA class I-restricted antigenic peptides
corresponding to cancer-related epitopes for recognition by
CTL is one potential strategy for tumor vaccination [4]. In
the immunostimulatory context, these antigens then acti-
vate T cells that ﬁnally enter the periphery of the body and
target the tumor. The complexity of the molecular and
cellular mechanisms involved in antigen processing, pre-
sentation and recognition renders this approach highly
vulnerable to failure. Concomitant with the development of
immunotherapeutic protocols, there is therefore an urgent
need for efﬁcient approaches to identify the functionally
most relevant peptide epitopes and monitor the presence of
antigen-speciﬁc T cells in a patient [5].
At present, various functional assays exist to quantitate
and characterize antigen-speciﬁc T-cell reactivities.
Enzyme-linked immunospot (ELISpot) [6], intracellular
cytokine staining (ICS) [7] as well as quantitative reverse
transcription polymerase chain reaction (qRT-PCR) [8]
represent functional T-cell assays that analyze antigen-
induced cytokine proﬁles. ELISpot provides the best char-
acterizedandmostrobustassay with a sensitivityofdown to
1:100,000 to detect a tumor antigen-speciﬁc T-cell response
[9]. In contrast to the functional assays, HLA multimer
(tetramer)-basedassaysyieldquantitative,butnotfunctional
data by staining epitope-speciﬁc T-cell receptors with an
intermediate detection limit. However, for each T-cell epi-
tope, an individual tetramer has to be produced and charac-
terized, making labor-intensive controls necessary [5].
For the characterization of T cells, current data support
the use of a functional assay such as the ELISpot or ICS in
conjunction with a phenotyping assay like HLA multimers
[9]. However, in the clinical situation the sampling of
blood is restricted and most T-cell assays are highly cell
consuming, thus limiting extensive immune monitoring.
Similarly, for epitope identiﬁcation, it is highly advanta-
geous to employ T cells that have undergone a minimum
number of expansion cycles.
In the analysis of gene expression, microarrays have
revolutionized the way experiments are conducted with
respect to miniaturization and parallelization. Given the
minimumofbiologicalmaterialrequired,alsoattemptshave
been made to exploit the beneﬁts of microarrays for cellular
assays including the detection of MHC-speciﬁc T-cell
responses. In one case, tetramers of MHC–peptide com-
plexes were spotted and the antigen-speciﬁc T cells detected
by cell capture on the spots and activation of calcium sig-
naling [10]. In a modiﬁcation of this approach, capture
antibodies for cytokines were co-immobilized with the
MHC–peptide complexes. In this way, physiologically
relevant T-cell responses could be detected [11, 12].
Nevertheless, the ultimate goal for the detection and char-
acterization of CTL should be a miniaturized assay that
directly probes for cell killing. Moreover, MHC–peptide
complexesandantibodymolecules,oncespottedonthearray
are prone to denaturation. In contrast, MHC-binding pep-
tides are highly stable. Therefore, the spotting of peptides
instead of protein complexes would be very advantageous.
Here, we show that the spotting of mixtures of MHC-
binding peptide epitopes and polylysine on hydrogel-
coated glass slides provides a powerful answer to these
challenges. Target cells adhere to peptide spots only and
presentation of the spotted peptides is conﬁned to each
spot. As a readout of cytolytic activity, cellular release of
the ﬂuorescent dye calcein [13] and detachment of cells are
employed. Cytolytic activity could be detected down to
0.5% antigen-speciﬁc cytotoxic T cells corresponding to
only 1,000 antigen-speciﬁc T cells on three peptide spots.
Moreover, we could also detect the presence of different
cytolytic activities in parallel, thereby enabling a proﬁling
of T-cell activities.
Materials and methods
Cells and peptides
The MUC-1- and CMV-negative and HLA-A*0201-posi-
tive [14] human melanoma cell line SK-Mel-24 [15] was a
kind gift from P. Walden, Charite ´, Berlin. CMV- and
MUC-1-speciﬁc CTLs were isolated and expanded as
described below. All peptides were kindly provided by
S. Stevanovic ´ (Department of Immunology, Interfaculty
Institute for Cell Biology, University of Tu ¨bingen, Germany).
The following HLA-A*0201-binding peptides were used:
the human cytomegalovirus-derived epitope HCMV
pp65495-503 (NLVPMVATV) (protein accession number
(swissprot) P06725) [16] and the RNA-dependent helicase-
derived peptide DDX17146-154 (p68) (Q92841) (YLLPAIVHI)
[17]. The mucin (MUC)-1 derived epitope M1.2 (P15941)
[18] was modiﬁed in anchor position 12 (L to K) to
enhance HLA-A*0201 binding (KLLLTVLTV).
Antigen-presenting cells (APCs):
DCs and CD40L-activated B-cell lines
Monocyte-derived DCs were generated as previously
described [19] and activated with 10 ng/ml tumor necrosis
factor-a, 10 ng/ml interleukin (IL)-1b, 1,000 U/ml IL-6 (all
R&D Systems) and 1 lg/ml prostaglandin E2 (Calbiochem,
La Jolla, CA, USA) for 24 h. DCs were characterized by
CD83 and CD80 expression and analyzed by ﬂow cytom-
etry. The culture of B cells was performed as described by
Schultze et al. [20], who provided the cell line t-CD154
(NIH-3T3 cells expressing human CD154). After 3 weeks,
the population contained predominantly B cells ([90%
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? cells). APCs were washed twice with serum-free
X-Vivo 15medium(Biowhittaker)andloadedfor1–2 hwith
5 lg/ml of the HLA-A*0201-binding epitopes of interest. In
24-wellplates (Nunc), 1 9 10
5effectorcellswerecocultured
with antigen-pulsed c-irradiated (32 Gray) APCs.
In vitro priming and expansion of peptide-speciﬁc
T cells
Healthy donors were selected on the basis of HLA-A*02
antigen expression as well as CMV seropositivity. Blood
samples were obtained after written informed consent from
the Department of Transfusion Medicine, University of
Tu ¨bingen, Germany. Peripheral blood mononuclear cells
(PBMCs) were isolated from heparinized blood by Ficoll–
Hypaque (Pharmacia, Uppsala, Sweden) density centrifu-
gation. PBMCs were cocultured with autologous peptide-
pulsed dendritic cells (DCs) at a ratio of 10:1 for 7 days
followed by repeated stimulation cycles using peptide-
pulsed CD40L-activated B cells (ratio: 4:1) in T-cell
medium [20, 21]. Initially, cultures contained IL-12 p70
(5 ng/ml, PromoKine, Heidelberg, Germany) substituted
by IL-7 (10 ng/ml, R&D Systems) during restimulation.
Expansion of T cells was supported by addition of IL-2
(Chiron, Emeryville, CA, USA). After three to four rounds
of stimulations, the cultures consisted predominantly of
CD8
? T cells. CD8
? T cells were magnetically enriched by
negative selection using a CD8 T-cell isolation kit (Milt-
enyi Biotech, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. Enrichment was always
[80%. Preparation of antigen-presenting cells (APCs) was
performed as described in the supplements.
Cytotoxic T-cell assay
The cytolytic activities of T-cell lines were tested in a
standardized chromium release assay. Speciﬁc lysis was
calculated according to the following formula:
% Lysis ¼ð ½ experimental cpm
  spontaneous cpm =½maximal cpm
  spontaneous cpm Þ   100:
Here, peptide-pulsed T2 cells, a transporter associated with
antigen presentation-deﬁcient HLA-A*0201
? cell line
(American Type Cell Collection (ATCC), CRL-No.: 1992,
Rockville, MD, USA), were used as target cells. T2 cells
were pulsed for 1–2 h with 5 lg/ml peptides in serum-free
media.
HLA-peptide monomers and ﬂow cytometry
Biotinylated recombinant HLA-A*0201-molecules and
ﬂuorescent HLA-tetramers were produced as described
previously [22]. Brieﬂy, ﬂuorescent tetramers were gener-
ated by incubating biotinylated HLA-monomers with
streptavidin-PE or streptavidin-APC (Molecular Probes,
Leiden, Netherlands) at a 4:1 M ratio. FACS analyses were
performed with tetramer-PE/APC plus antibody CD8-
PerCP (BD Bioscience, Heidelberg, Germany). Cells were
incubated with antibodies at 4C for 20 min in the dark,
followed by 30 min incubation with ﬂuorescent HLA-tet-
ramers at the same conditions. Cells were analyzed on a
four-color FACSCalibur cytometer (BD).
Preparation of microarrays
Hydrogel-coated glass slides were from Perkin Elmer
(Ju ¨gesheim, Germany). Peptide microarrays were gener-
ated using a piezo-driven contact-free nanopipettor
(Nanoplotter 2.0, GeSiM, Grosserkmannsdorf, Germany).
Working dilutions of 1 mg/ml peptide stock solutions were
prepared immediately before use, according to the fol-
lowing procedure: peptide stock solutions were placed in
an ultrasonic bath at room temperature for 3 min, diluted to
60 lM in PBS containing 0.01% poly-L-lysine 70,000-
150,000 g/mol (Sigma–Aldrich), mixed on a vortexer,
placed in an ultrasound bath for 1 min and spun down. Into
a 384-well plate, 30 ll of this peptide solution was trans-
ferred and used immediately for the production of peptide
microarrays with the nanopipettor. Hydrogel slides were
placed on a plate cooled to dew point (15C) using a
Polystat CC3 (Peter Huber Ka ¨ltemaschinenbau GmbH,
Offenburg, Germany). For each spot, a total volume of
1.2 nl was pipetted. The microarrays were dried at room
temperature and used within 2 days after preparation. The
peptide spots had a diameter of 200–300 lm and a center-
to-center distance of 450 lm.
Microarray experiments
For the generation of incubation chambers, 10 9 10 mm
GeneFrames (Peqlab, Erlangen, Germany) were taped on
hydrogel-coated slides (Fig. 1). By taping a quarter corner
of a GeneFrame into the ﬁrst GeneFrame, 4 9 4m m
incubation chambers for 6 9 6 peptide arrays were
obtained. One hydrogel-coated slide contained up to three
such incubation chambers in parallel. The slide was then
placed into a covered 24 cm sterile Petri dish containing
wet ﬁlter papers placed to avoid dry fall of the arrays
during incubation. Prior to the incubation with cells, the
arrays were washed 29 1 min and 19 10 min with 50 ll
PBS at room temperature to remove excessive peptide
from the spots. Care was taken to avoid drying of the
array.
SK-Mel-24 cells were harvested by trypsination using
0.05%/0.02% Trypsin/EDTA solution for 3 min at 37C,
Cancer Immunol Immunother (2010) 59:1379–1387 1381
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6 cells/ml and
stained with 0.1 lM calcein-AM (Merck Biosciences,
Darmstadt, Germany) in medium for 20 min at room tem-
perature, washed again and re-adjusted to 1 9 10
6 cells/ml.
In 25 ll medium, 2.5 9 10
4 SK-Mel-24 was applied as
targets to a 4 9 4 mm array and incubated for 3 h at 37C.
Cells that had not attached at the end of this period were
removed by careful washing of the array.
Before addition of T cells, the array was imaged by
scanning in a mosaic-like fashion using an LSM510 laser
scanning microscope equipped with a 109 0.3 NA objec-
tive. Detection was non-confocal. Fluorescence was excited
using the 488 nm line of an argon–ion laser and detected
using an LP505 long pass ﬁlter. T cells were washed once
with fresh, preheated (37C) T-cell medium (RPMI-1640,
10% HS, Pen/Strep, 200 lM L-glutamine) and adjusted to a
density of 8 9 10
6 cells/ml. To each 4 9 4 mm array,
2 9 10
5 peptide-expanded, CD8
?-sorted T cells were
added and incubated for 2 h at 37C/5%CO2. Arrays were
imaged every 30 min to determine time-dependent loss of
target cells. After 2 h, the array was washed with warm
X-vivo-15 medium to remove lost cells and imaged again to
determine total cell loss. Image processing was carried out
with Image Pro4.5.1 (MediaCybernetics, Silver Spring,
USA) as described in the supplements.
Image processing
Imaged processing was performed with the confocal ima-
ges of calcein ﬂuorescence. Fluorescence background
between cells was removed by multiplication with a binary
mask that was created from a copy of the original image
using an intensity threshold so that only signals of cells
were included as valid pixels. Holes in this mask were
closed using morphological ﬁlters. Spot size, spot ﬂuores-
cence intensity and cell count were measured on a spot-by-
spot basis. Data were exported into Excel 2003 (Microsoft)
for further data analysis. The fractions of the spot area, spot
intensity and cell count after the end of the experiment
were related on a spot-by-spot basis to the values obtained
prior to incubation with T cells.
Results
Detection of cytotoxic activity in the microarray format
We had observed previously that peptides, immobilized
non-covalently on the surface of a microarray substrate,
may be transferred locally onto cells contacting the sur-
face [23]. The use of hydrogel-coated slides in combi-
nation with low concentrations of polylysine in the
spotting buffer of the peptide solution conﬁned the cell
attachment to the peptide spots. The co-administration of
poly-L-lysine rendered the cell attachment independent
from the physicochemical characteristics of the peptide. A
hydrogel is a polymer network with the ability to take up
large amounts of water. In this case, a polyacrylamide-
based hydrogel was employed [24]. In the dry state, this
gel had a thickness of 4 lm. According to the manufac-
turer’s speciﬁcations, in the hydrated state the gel swelled
to up to 20 lm.
Fig. 1 Detection of CTL activity using peptide microarrays. a Peptide
microarrays are generated by spotting of mixtures of the peptide and
poly-L-lysine on hydrogel-coated glass slides. b Target cells, loaded
with the cell tracer calcein, only settle on peptide spots and locally
take up and present the peptide. CTL activity is detected by
detachment of targets and calcein release using a confocal microscope
(c). d Incubation chambers on hydrogel-coated slides. Smaller
incubation chambers of a quarter of the original GeneFrame were
obtained by taping an edge of another GeneFrame into the original
incubation chamber
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were pipetted in the form of a regular microarray. As much
as 1.2 nl of peptide solution was pipetted for each spot.
Peptides were spotted from a 60 lM solution. In related
experiments, this concentration had provided the best
results for local T-cell activation without detectable cross-
contamination between individual spots (results not
shown). The peptide spots had a diameter of about 200–
300 lm. With a center-to-center spacing of 450 lm, 36
spots could be tested on a surface of only 4 9 4 mm.
Incubation chambers corresponding to the size of the
peptide microarray were created by using commercially
available self-adhesive frames that are typically employed
for the generation of incubation chambers for the hybrid-
ization of oligonucleotides (Fig. 1).
As a representative for an epitope overexpressed on
tumor cells, a human mucin-1 (MUC-1)-derived peptide
was employed [18]. MUC-1 is a membrane-associated
glycoprotein that is overexpressed on epithelial tumors
such as breast and ovarian cancer and might prove as a
target for humoral and cellular immune responses [25].
One of the predominant viral antigens is the lower matrix
65-kDa phosphoprotein (pp65) of cytomegalovirus (CMV).
CTLs may readily be generated from the blood of sero-
positive individuals by the use of antigen-presenting cells
pulsed with deﬁned virus epitopes such as HLA-A*0201-
restricted pp65495–503 [16]. Finally, the RNA-dependent
helicase-derived peptide DDX17146–154 (p68) represents a
well-deﬁned self ligand with high afﬁnity to HLA-A*0201
[17]. Because of the lack of corresponding T cells, p68 is
commonly used as a negative control in several immuno-
diagnostic assays.
As target cells, adherently growing SK-Mel-24 cells
were chosen [26]. This melanoma-derived cell line is
positive for HLA-A*0201 and negative for the antigens
that we had selected as test antigens. Adherently growing
cells were preferred over suspension cells. Even though the
time for peptide loading was not sufﬁciently long to allow
for spreading of the cells on the surface, also after careful
washing, the SK-Mel-24 cells completely covered the spots
(100–150 cells/spots). In comparison, suspension cells
such as B cells were largely washed off the surface. SK-
Mel-24 cells were loaded with the membrane-permeable
acetoxymethylester (AM) of the ﬂuorescent cell tracer
calcein. Inside the cell, this ester is rapidly hydrolyzed
rendering the dye membrane impermeable. Calcein release
upon CTL-induced membrane damage had been used as a
ﬂuorescence-based alternative to the chromium-release
assay previously [13].
In a ﬁrst experiment, we were interested to learn whe-
ther using the microarray format and calcein-based detec-
tion of membrane damage, CTL activity could be
speciﬁcally detected. For this purpose, on a 6 9 6 spot
array, three rows each of the CMV-derived epitope and the
p68 peptide were spotted (Fig. 2). After a 3 h incubation
period with SK-Mel-24 cells, CMV antigen-expanded,
Fig. 2 Detection of CTL activity on cellular peptide microarrays.
SK-Mel-24 cells, serving as targets, were stained with 0.1 lM calcein
(AM) and incubated at a density of 2.5 9 10
4 cells for 3 h on a 6 9 6
spot array containing 18 spots each of the CMV and of a p68 control.
After careful washing to remove loose cells, incubation for 2 h with
2 9 10
5 CMV-expanded CD8
? T cells and a further washing step
images were recorded. a, b, d, e Representative spots for CMV (a, d)
and p68 (b, e) presenting targets before (a, b) and after (d, e)
incubation with CMV-expanded T cells. c, f Overview of the cellular
peptide microarray before (c) and after (f) incubation with CMV-
expanded CTL. The scale bar in e corresponds to 100 lm, the one in f
to 400 lm. g, h Characterization of CMV-reactive CTLs by standard
51Cr release assays. PBMCs of the same HLA-A*0201-positive
human donor were stimulated with CMV peptide loaded (pp65495–503)
autologous APCs. After four rounds of stimulations, T cells were
tested by g tetramer staining as well as by h
51Cr release assay.
g Double staining using anti-CD8-PerCP together with PE-labeled
A2/CMV tetramers show 5.9% T cells. Staining with an irrelevant
tetramer (A2/HIV) revealed 1.2% background staining. h Cytolytic
activity was analyzed in a standard 4 h
51Cr release assay against
HLA-A*0201?T2 cells loaded with CMV peptides (ﬁlled square), T2
cells loaded with p68 as negative control (ﬁlled triangle) or K562
cells (ﬁlled diamond) to show NK cell dependent lysis
Cancer Immunol Immunother (2010) 59:1379–1387 1383
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?-sorted T cells with a fraction of antigen-speciﬁc
cells of 6%, corresponding to 25% antigen-speciﬁc killing
in a
51Cr release assay, were added. The efﬁciency of
antigen presentation and T-cell activation was time
dependent. A maximum was reached after 2–3 h (data not
shown).
T cells were added at a density of 2 9 10
5 cells on a
6 9 6 cellular peptide microarray. This relatively high
density enhanced the chances of an encounter of antigen-
speciﬁc T cells with target cells on a cellular peptide spot
displaying its speciﬁc antigen. After 2 h and a brief
washing of the array, inspection by ﬂuorescence and
transmission light microscopy revealed a complete loss of
targets on all CMV spots. In contrast, on the p68 spots, a
major part of the cells and of the ﬂuorescence was still left.
This result demonstrates that on the hydrogel-coated slide,
the peptides were present in a form competent for binding
to MHC molecules. Though one may assume that a sig-
niﬁcant part of the peptides had been released into the
medium, on the spot cells were exposed to a depot of the
peptide at a higher active concentration. If peptides had
been released into the medium before binding to the MHC
molecules, cytolytic activity would not be conﬁned to the
spots bearing the CMV epitope. A parallel negative control
of targets on a peptide array without T cells was used as
control for cell loss over time. As much as 20% of cells
were lost in a 2-h incubation period. Moreover, we were
concerned by a possible inﬂuence of the calcein stain on
cytolytic activity. A reduction in cytolytic activity was
observed when target cells were incubated with the dye at a
concentration of 1 lM. At a concentration of 0.1 lM, no
such effect could be detected (not shown).
Time dependence of cytolytic activity
Next, we were interested to follow the cytolytic activity
over time. Furthermore, we were interested in comparing
quantitatively the lysis of cells on epitopes recognized by
CTLs and controls. Thus, three rows of the CMV-derived
and the p68-derived epitopes were spotted followed by
incubation with calcein-loaded targets for peptide presen-
tation. Then CTLs were added and the microarrays imaged
over time (Fig. 3). For the CMV spots, there was a dis-
persion of cells already after 30 min. At 2 h after addition
of CTLs, cells were completely dispersed. For the p68
controls, only 3 out of 18 spots had lost a major part of
their cells. A brief washing of the array removed nearly all
cells from the CMV spots. In contrast, for the p68 spots,
except for three, the cell layers were still present.
The quantitative analysis of cell death proceeded on the
basis of calcein ﬂuorescence. Three parameters were con-
sidered: The spot size (cells on the spot), the total intensity
of all cells of a spot and the cell count per spot relative to
the respective original value. For both, the CMV spot as
well as the p68 controls, the average of all three values
decreased over time (Fig. 3h, j, l). However, for the CMV
Fig. 3 Time course of cytolytic activity of CMV-expanded CD8
? T
cells on a cellular peptide microarray. a–e Time series of the cytolytic
activity of CMV-expanded T cells against calcein-loaded SK-Mel-24
cells incubated on CMV and p68 peptide spots for 3 h. The array was
scanned at the indicated time points and after a ﬁnal washing step.
The scale bar corresponds to 500 lm. f–l Quantiﬁcation of cytotoxic
activity; f averages of all spots after 2 h and washing. Error bars
correspond to the standard deviations of all spots. Signiﬁcance was
determined by a paired Student’s t test. g–l Time course of (g, h) spot
size, (i, j) spot intensity and (k, l) cell numbers per spot relative to the
initial value for or each individual spot (g, i, k) and the average of all
spots (h, j, l)
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the loss of signal from p68 spots was very likely due to
some higher background killing by the CTL, as indicated
by a standard
51Cr release assay (Fig. 4f). For all three
parameters, there was a constant difference over the time
course of the experiment. When instead of the averages the
values for individual spots were considered (Fig. 3g, i, k),
it was apparent that for CMV the individual values varied
much stronger than for the control peptide. For the control,
there was a homogenous decrease for all three parameters
over the time course of the experiment. The increased
variation of the CMV spots was due to the fact that for
some of the spots, detached cells were still present above
the spot area. After washing, the values for the CMV and
p68 spots clearly differed from one another. For only 7 out
of 36 spots did the tested parameters overlap. All three
parameters performed comparably well, with the straight-
forward assessment of total spot intensity yielding a
slightly better separation of control versus epitope than the
other two parameters.
Simultaneous detection of T-cell epitopes
After having established a quantitative protocol for the
detection of cytolytic activity using the peptide micro-
arrays, ﬁnally, we were interested to simultaneously detect
different CTL activities and evaluate the detection limit.
Next to the CMV epitope, a breast cancer-associated MUC-
1 epitope was included on the array (Fig. 4). In this case,
instead of splitting the whole array into two different areas,
the epitope spots were distributed over the whole array. In
this way, we further addressed whether speciﬁc killing
remained restricted to the epitope spots. In each case, the
arrays were incubated with 2 9 10
5 CD8
? T cells. If only
CMV-expanded CTL were present at a frequency of 5%,
corresponding to 10,000 cells, killing was restricted to
targets seeded on CMV spots. In contrast, as soon as MUC-
1-speciﬁc CTL were added, killing was also observed for
cells on MUC-1 spots. Speciﬁc killing was observed for as
little as 0.5% epitope-speciﬁc CTL, as quantiﬁed by tet-
ramer staining. It is noticeable that the presence of MUC-1-
expanded cells led to more variation of remaining cells on
the p68 spots. This observation may be explained by the
fact that also in the standard
51Cr release assay, the MUC-
1-expanded CTL showed more unspeciﬁc killing of p68-
loaded cells than the CMV-expanded cells.
Discussion
Our results demonstrate a full reconstitution of antigen
presentation, recognition and cytolytic activity in a
microarray-based format that only requires about 6 h for
the total protocol and operates with an unprecedented low
Fig. 4 Parallel detection of different CTL activities on a cellular
peptide microarray. CMV and MUC-1-expanded CD8
? T cells were
added to SK-Mel-24 cells that had been incubated on a microarray
containing three CMV- (squares) and MUC-1 (circles) peptide spots
surrounded by spots of p68 control peptide for 3 h. Images of the
array before (a) and after (b) 2 h incubation including washing with
2 9 10
5 CMV-expanded T cells. c, d Fluorescence intensities of
spots on arrays incubated (c) with 2 9 10
5 CMV-expanded cells (5%
tetramer positive cells, 10,000 cells), and (d) a mixture of 1 9
10
5 CMV- and 1 9 10
5 MUC-1-expanded CTL (2.5 and 0.5% tetra-
mer positive T cells (corresponding to 5,000 and 1,000 antigen-
speciﬁc T cells, respectively). P values were determined by a paired
Student’s t test. e, f Characterization of CMV- and MUC-1-reactive
CTLs by standard
51Cr release assays. PBMCs of an HLA-A*02-
positive human donor were stimulated with either (e) MUC-1-peptide
(M1.2mod) or (f) CMV peptide (pp65495-503) loaded to autologous
APCs. After three rounds of stimulations, T cells were tested in a
standard 4 h
51Cr-release assay against HLA-A*0201-positive T2
cells loaded with the respective antigenic peptides (ﬁlled square), T2
cells loaded with p68 as negative control (ﬁlled triangle) or K562
cells (ﬁlled diamond) to show NK cell-dependent lysis
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123number of cells. The simultaneous detection of two dif-
ferent T-cell activities illustrates that induction of antigen
presentation and killing was not a serendipitous ﬁnding for
the CMV peptide, but instead a principle that readily
applies to other MHC class I-restricted epitopes.
On ﬁrst sight, the use of peptides instead of peptide–
MHC complexes as demonstrated in prior approaches [10–
12] may be considered an enormous increase in the com-
plexity of the assay. Using peptide microarrays, peptide
uptake and presentation also have to occur on the array.
This initial step requires the incubation of the array with
target cells prior to the application of T cells. Due to the
absence of physical boundaries between individual peptide
spots, cross-contamination during antigen uptake therefore
has to be considered. For RNA and small molecules, a
localized transfer of molecules onto cells had been shown
[27, 28]. However, for peptides such an application has not
been published. The chemical stability and ease of synthesis
of large collections of synthetic peptides [29] in comparison
to the generation of MHC–peptide complexes constitutes a
major advancement over published microarray-based
strategies for the monitoring of T-cell activities.
Moreover, with respect to the monitoring of CTL
responses, the detection of the actual cytolytic activity
should be preferred over the detection of cytokines as
surrogate markers. In pathologic situations such as chronic
viral infection or cancer, many CTL, in spite of expressing
cytokines, lack cytolytic activity [30–32]. Using a viral and
a tumor-derived HLA-A*0201-restricted epitope, the kill-
ing by antigen-expanded CTL was directly visualized on
the array.
By performing standard
51Cr release assays on the same
T-cell populations that were used for the microarray
experiments, we conﬁrmed that killing was MHC class I
and peptide restricted. No killing was observed for K562
cells conﬁrming the absence of NK cell-mediated lysis. In
addition, we would like to point out that due to the pres-
ence of cells presenting speciﬁc and control epitopes side
by side, the microarray-based format inherently controls
for the restriction of killing for speciﬁc MHC–peptide
complexes.
Currently, we foresee the major application of the pep-
tide microarrays in epitope identiﬁcation. In comparison to
the identiﬁcation of T-cell frequencies in patient samples, in
epitope identiﬁcation constraints on detection sensitivity are
less severe. Still, these assays will beneﬁt enormously from
approaches that require rather little expansion of T cells
from patient isolates and enable the acquisition of T-cell
response proﬁles by parallel testing of several epitopes.
Nowadays, candidate tumor antigen-derived peptides for
cancer vaccination may be predicted by computational
algorithms [33] or by sequencing of naturally presented
peptides eluted from HLAs of tumor tissues [34]. In
addition, epitope mapping of cancer and pathogen-associ-
ated proteins is a commonly employed method for the
identiﬁcation of relevant CTL epitopes [35, 36]. All
methods critically depend on the methods for a functional
validation of CTL activity. In the development of cancer
vaccines, a direct testing of cytolytic activity, as provided
by our arrays, represents the most relevant readout.
In summary, our peptide microarray-based approach
implements the whole process of antigen presentation and
recognition in a peptide microarray format. Currently, with
respect to sensitivity, ELIspot remains the gold standard
with a sensitivity of 1:50,000 to 1:100,000. However, this
assay does not enable a detection of cytolytic activity. To
our knowledge, there is currently no method that can
functionally detect cytolytic activity with fewer cells than
our microarrays. For the characterization of candidate
epitopes for peptide-based cancer vaccines and ultimately
also for monitoring of vaccination success in CTL from
patients, our microarray-based method therefore enables
functional studies that were not possible before.
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